심방세동 환자에서 주요 항부정맥제의 전기생리 작용의 차이
Differing Electrophysiological Effects of Various Antiarrhythmic Drugs on the Cardiac Chamber in Atrial Fibrillation
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims:Long-term antiarrhythmic drug therapy remains the principal approach for suppressing atrial fibrillation (AF) and maintaining sinus rhythm. In this study, we examined the differing electrophysiological effects of various antiarrhythmic drugs on the cardiac chamber and atrial selectivity in patients with AF. Methods:We analyzed 134 patients (60.4 ± 12.5 years, M:F = 1.14:1) who were administered a single antiarrhythmic agent for AF over 6 months: amiodarone (group A), flecainide (group F), or propafenone (group P). The P wave, QRS complex duration and dispersion, and QT interval and its dispersion were evaluated using a standard 12-lead electrocardiogram. Results:There was no significant difference in age, gender ratio, or associated diseases among the three groups. In group A, Pmax, Pmin, P dispersion, QRSmax, QRSmin, and QRS dispersion were shorter than in groups F and P, whereas Pmax/QRSmax was the highest in group A (A = 1.2, F = 0.9, P = 1.0; p < 0.01). QTcmax and QTcmin were longer in group A, whereas QTc dispersion and the QT peak to end (A = 13.3 ± 11.2, F = 30.7 ± 24.9, P = 31.8 ± 21.6; p < 0.01) were shorter in group A than in the other groups. Conclusions:Amiodarone had a weaker, but more selective, inhibitory effect on intra-atrial conduction, and inhibited ventricular repolarization more effectively and homogenously than flecainide or propafenone. These differing electrophysiological effects may contribute to the superior effectiveness and safety of amiodarone over flecainide or propafenone. (Korean J Med 2011;80:672-679)
Abstract
Background/Aims:Long-term antiarrhythmic drug therapy remains the principal approach for suppressing atrial fibrillation (AF) and maintaining sinus rhythm. In this study, we examined the differing electrophysiological effects of various antiarrhythmic drugs on the cardiac chamber and atrial selectivity in patients with AF. Methods:We analyzed 134 patients (60.4 ± 12.5 years, M:F = 1.14:1) who were administered a single antiarrhythmic agent for AF over 6 months: amiodarone (group A), flecainide (group F), or propafenone (group P). The P wave, QRS complex duration and dispersion, and QT interval and its dispersion were evaluated using a standard 12-lead electrocardiogram. Results:There was no significant difference in age, gender ratio, or associated diseases among the three groups. In group A, Pmax, Pmin, P dispersion, QRSmax, QRSmin, and QRS dispersion were shorter than in groups F and P, whereas Pmax/QRSmax was the highest in group A (A = 1.2, F = 0.9, P = 1.0; p < 0.01). QTcmax and QTcmin were longer in group A, whereas QTc dispersion and the QT peak to end (A = 13.3 ± 11.2, F = 30.7 ± 24.9, P = 31.8 ± 21.6; p < 0.01) were shorter in group A than in the other groups. Conclusions:Amiodarone had a weaker, but more selective, inhibitory effect on intra-atrial conduction, and inhibited ventricular repolarization more effectively and homogenously than flecainide or propafenone. These differing electrophysiological effects may contribute to the superior effectiveness and safety of amiodarone over flecainide or propafenone. (Korean J Med 2011;80:672-679)
참고문헌 (29)
- Alpert JS, "Atrial fibrillation: natural history, complications, and management", Annu Rev Med, 39, pp.41~52 (1988)
- Krahn AD, "The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study", Am J Med, 98, pp.476~484 (1995)
- Kannel WB, "Epidemiologic features of chronic atrial fibrillation: the Framingham Study", N Engl J Med, 306, pp.1018~1022 (1982)
- Wazni OM, "Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial", JAMA, 293, pp.2634~2640 (2005)
- Jaïs P, "Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 Study", Circulation, 118, pp.2498~2505 (2008)
- Bonanno C, "Efficacy and safety of catheter ablation versus antiarrhythmic drugs for atrial fibrillation: a meta-analysis of randomized trials", J Cardiovasc Med (Hagerstown), 11, pp.408~418 (2010)
- Burashnikov A, "Atrial-selective sodium channel blockers: do they exist", J Cardiovasc Pharmacol, 52, pp.121~128 (2008)
- Deal KK, "Molecular physiology of cardiac potassium channels", Physiol Rev, 76, pp.49~67 (1996)
- Burashnikov A, "Can inhibition of IKur promote atrial fibrillation", Heart Rhythm, 5, pp.1304~1309 (2008)
- Schram G, "Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects", Br J Pharmacol, 142, pp.1300~1308 (2004)
- Antzelevitch C, "Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties", Circulation, 110, pp.904~909 (2004)
- Suttorp MJ, "The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm", J Am Coll Cardiol, 16, pp.1722~1727 (1990)
- Grundy SM, "Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines", Circulation, 110, pp.227~239 (2004)
- American Diabetes Association, "Standards of medical care in diabetes: 2009", Diabetes Care, 32(Suppl 1), pp.S13~S61 (2009)
- Lang RM, "Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of echocardiography, a branch of the European Society of Cardiology", J Am Soc Echocardiogr, 18, pp.1440~1463 (2005)
- Bazett H, "An analysis of the time relationships of the heart", Heart Rhythm, 7, pp.353~370 (1920)
- Fuster V, "ACC", AHA, American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation), pp.J Am Coll Cardiol, 2006[DOI]
- Vassallo P, "Prescribing amiodarone: an evidencebased review of clinical indications", JAMA, 298, pp.1312~1322 (2007)
- Roy D, "Amiodarone to prevent recurrence of atrial fibrillation: Canadian Trial of Atrial Fibrillation Investigators", N Engl J Med, 342, pp.913~920 (2000)
- Vaughan Williams EM, "Classifying antiarrhythmic actions: by facts or speculation", J Clin Pharmacol, 32, pp.964~977 (1992)
- Chun SH, "Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter", Am J Cardiol, 76, pp.47~50 (1995)
- Hohnloser SH, "Electrocardiographic and antiarrhythmic effects of intravenous amiodarone: results of a prospective, placebo-controlled study", Am Heart J, 121, pp.89~95 (1991)
- Punnam SR, "Amiodarone - a 'broad spectrum' antiarrhythmic drug", Cardiovasc Hematol Disord Drug Targets, 10, pp.73~81 (2010)
- Juul-Möller S, "Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation", Circulation, 82, pp.1932~1939 (1990)
- Burashnikov A, "Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine", Circulation, 116, pp.1449~1457 (2007)
- Burashnikov A, "Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation", Heart Rhythm, 5, pp.1735~1742 (2008)
- Chaudry II, "QT interval effects of normal QRS variation", Am J Cardiol, 74, pp.628~629 (1994)
- Sundqvist K, "Cardiac repolarization properties during standardized exercise test as studied by QT, QT peak and terminated T-wave intervals", Clin Physiol, 9, pp.419~425 (1989)
- Merri M, "Electrocardiographic quantitation of ventricular repolarization", Circulation, 80, pp.1301~1308 (1989)